|
Release Date
12/6/2012 Expiration Date
12/6/2013 This program has expired. CME credit is no longer available. |
|
|
|
|
|
|
 |
Nezam Afdhal, MD Beth Israel Deaconess Medical Center Boston, MA
|
|
|
 |
|
|
|
|
|
 |
Kim Brown, MD Henry Ford Hospital Detroit, MI |
|
|
 |
|
|
|
|
|
 |
Jordan Feld, MD Toronto Western Hospital Liver Center Toronto, Canada |
|
|
 |
|
|
|
|
|
 |
Michael Fried, MD University of North Carolina Chapel Hill, NC |
|
|
 |
|
|
|
|
|
 |
Ira Jacobson, MD Weill Cornell Medical College New York, NY |
|
|
 |
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
Jordan Feld, MD Toronto Western Hospital Liver Center Toronto, Canada |
Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld completed a clinical research fellowship in hepatology after which he spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health.
Dr. Feld returned to Toronto to join the faculty of the University of Toronto as an Assistant Professor of Medicine and clinician-scientist based at the Toronto Western Hospital Liver Center and the Sandra Rotman Centre for Global Health. His laboratory work focuses on understanding treatment non-response in hepatitis C infection and, more broadly, on understanding the antiviral immune response with the goal of developing new strategies for the treatment of viral hepatitis.
Speaker Disclosure:
Jordan Feld, MD, has served as a consultant for and has participated on the speaker’s bureaus for Abbott, Gilead, Merck, Roche, and Vertex. He has participated on the advisory boards for Abbott, BI, Gilead, Merck, Roche, and Vertex. |
|